- Home
- NRXP vs CRBP Comparison
NRXP vs CRBP Comparison
Compare NRXP & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRXP | CRBP |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 168.3M |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NRXP | CRBP |
|---|---|---|
| Price | $3.24 | $10.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $38.25 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 1.1M | 278.0K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.70 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,225,000.00 | ★ $4,822,272.00 |
| Revenue This Year | $2,547.84 | N/A |
| Revenue Next Year | $1,591.73 | $116.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.65 | $7.12 |
| 52 Week High | $5.06 | $20.56 |
Technical Indicators
Market Signals| Indicator | NRXP | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 40.93 | 64.19 |
| Support Level | $2.88 | $9.68 |
| Resistance Level | $3.33 | $10.74 |
| Average True Range (ATR) | 0.32 | 0.52 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 30.83 | 93.24 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.